IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication

Floriana Barbera, Giovanna Russelli, Loredana Pipitone, Giada Pietrosi, Sveva Corsale, Giovanni Vizzini, Bruno Gridelli, Pier Giulio Conaldi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients. This study evaluated the association between SNPs rs12980275, rs12979860 and rs8099917 and treatment outcome of HCV recurrent infection in HCV-positive patients who underwent liver transplant. We aimed to assess to what extent recipient and/or graft donor IL28B polymorphisms contribute to HCV clearance after transplantation influencing the response to the antiviral treatment. We found that the allele frequencies in donors were in agreement with the pattern expected in the European population. The frequency of favourable genotypes was significantly lower in recipients than in donors, reasonably because the recipients represented a group of patients affected by chronic Hepatitis C. Our study demonstrated that the positive outcome of the pegIFN-alpha/RBV treatment of HCV recurrence is associated with the co-presence of favourable genotypes of both donors and recipients. However, IL28B SNPs of the recipient seem to play a major role in this clinical setting. In particular, homozygosis of rs12979860 favourable genotype in recipients was associated with sustained virological response independently from the donor's genotype. Thus, identification of these SNPs may be useful to predict the response to IFN-based therapy of HCV recurrent infection in liver-transplanted patients.

Original languageEnglish
Pages (from-to)201-210
Number of pages10
JournalNew Microbiologica
Volume38
Issue number2
Publication statusPublished - Apr 1 2015

Fingerprint

Liver Transplantation
Single Nucleotide Polymorphism
Tissue Donors
Recurrence
Genotype
Ribavirin
Interferon-alpha
Transplants
Therapeutics
Liver
Chronic Hepatitis C
Infection
Gene Frequency
Antiviral Agents
Transplantation
Population

Keywords

  • Hepatitis C virus
  • Interferon
  • Interleukin 28B
  • Liver transplantation
  • Polymorphisms

ASJC Scopus subject areas

  • Microbiology (medical)
  • Medicine(all)

Cite this

IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication. / Barbera, Floriana; Russelli, Giovanna; Pipitone, Loredana; Pietrosi, Giada; Corsale, Sveva; Vizzini, Giovanni; Gridelli, Bruno; Conaldi, Pier Giulio.

In: New Microbiologica, Vol. 38, No. 2, 01.04.2015, p. 201-210.

Research output: Contribution to journalArticle

@article{2bd6874790f1474caa771515cd82b8a9,
title = "IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication",
abstract = "Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients. This study evaluated the association between SNPs rs12980275, rs12979860 and rs8099917 and treatment outcome of HCV recurrent infection in HCV-positive patients who underwent liver transplant. We aimed to assess to what extent recipient and/or graft donor IL28B polymorphisms contribute to HCV clearance after transplantation influencing the response to the antiviral treatment. We found that the allele frequencies in donors were in agreement with the pattern expected in the European population. The frequency of favourable genotypes was significantly lower in recipients than in donors, reasonably because the recipients represented a group of patients affected by chronic Hepatitis C. Our study demonstrated that the positive outcome of the pegIFN-alpha/RBV treatment of HCV recurrence is associated with the co-presence of favourable genotypes of both donors and recipients. However, IL28B SNPs of the recipient seem to play a major role in this clinical setting. In particular, homozygosis of rs12979860 favourable genotype in recipients was associated with sustained virological response independently from the donor's genotype. Thus, identification of these SNPs may be useful to predict the response to IFN-based therapy of HCV recurrent infection in liver-transplanted patients.",
keywords = "Hepatitis C virus, Interferon, Interleukin 28B, Liver transplantation, Polymorphisms",
author = "Floriana Barbera and Giovanna Russelli and Loredana Pipitone and Giada Pietrosi and Sveva Corsale and Giovanni Vizzini and Bruno Gridelli and Conaldi, {Pier Giulio}",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "38",
pages = "201--210",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2",

}

TY - JOUR

T1 - IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication

AU - Barbera, Floriana

AU - Russelli, Giovanna

AU - Pipitone, Loredana

AU - Pietrosi, Giada

AU - Corsale, Sveva

AU - Vizzini, Giovanni

AU - Gridelli, Bruno

AU - Conaldi, Pier Giulio

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients. This study evaluated the association between SNPs rs12980275, rs12979860 and rs8099917 and treatment outcome of HCV recurrent infection in HCV-positive patients who underwent liver transplant. We aimed to assess to what extent recipient and/or graft donor IL28B polymorphisms contribute to HCV clearance after transplantation influencing the response to the antiviral treatment. We found that the allele frequencies in donors were in agreement with the pattern expected in the European population. The frequency of favourable genotypes was significantly lower in recipients than in donors, reasonably because the recipients represented a group of patients affected by chronic Hepatitis C. Our study demonstrated that the positive outcome of the pegIFN-alpha/RBV treatment of HCV recurrence is associated with the co-presence of favourable genotypes of both donors and recipients. However, IL28B SNPs of the recipient seem to play a major role in this clinical setting. In particular, homozygosis of rs12979860 favourable genotype in recipients was associated with sustained virological response independently from the donor's genotype. Thus, identification of these SNPs may be useful to predict the response to IFN-based therapy of HCV recurrent infection in liver-transplanted patients.

AB - Single nucleotide polymorphisms (SNPs) of the IL28B locus are associated with a positive response to pegylated interferon-alpha and ribavirin (pegIFN-alpha/RBV) treatment of HCV-infected patients. This study evaluated the association between SNPs rs12980275, rs12979860 and rs8099917 and treatment outcome of HCV recurrent infection in HCV-positive patients who underwent liver transplant. We aimed to assess to what extent recipient and/or graft donor IL28B polymorphisms contribute to HCV clearance after transplantation influencing the response to the antiviral treatment. We found that the allele frequencies in donors were in agreement with the pattern expected in the European population. The frequency of favourable genotypes was significantly lower in recipients than in donors, reasonably because the recipients represented a group of patients affected by chronic Hepatitis C. Our study demonstrated that the positive outcome of the pegIFN-alpha/RBV treatment of HCV recurrence is associated with the co-presence of favourable genotypes of both donors and recipients. However, IL28B SNPs of the recipient seem to play a major role in this clinical setting. In particular, homozygosis of rs12979860 favourable genotype in recipients was associated with sustained virological response independently from the donor's genotype. Thus, identification of these SNPs may be useful to predict the response to IFN-based therapy of HCV recurrent infection in liver-transplanted patients.

KW - Hepatitis C virus

KW - Interferon

KW - Interleukin 28B

KW - Liver transplantation

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84930979162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930979162&partnerID=8YFLogxK

M3 - Article

C2 - 25938745

AN - SCOPUS:84930979162

VL - 38

SP - 201

EP - 210

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2

ER -